the solvents used in regard to local anesthetics were different; Mazoit et al used an electrolyte buffer with a pH of 6.9, whereas Ruan et al used a pH of 7.4 (blood serum). A previous study conducted by our team favored the LCT emulsion, because it provided less mortality after resuscitation in the rescue of bupivacaine-induced cardiac arrest when compared with an LCT/MCT emulsion. 11 Fettiplace et al 12 demonstrated that the lipid emulsion not only reduced toxicity but also improved cardiac performance in a physiologically based, pharmacokinetic, pharmacodynamic model. However, Park et al 13 reported that an LCT/MCT emulsion had more of a positive inotropic effect than that of an LCT emulsion, through increasing left ventricular systolic pressure in an ex vivo rat heart model via an increase of the intracellular calcium level. In 2013, we reported that 30% of LCT emulsion reduced the concentration of bupivacaine in the rat's heart, increased the concentration in the liver, and accelerated the clearance of bupivacaine. 14 It remains unclear as to which lipid emulsion is better, especially in pharmacokinetics when the LCT emulsion was associated with less mortality after resuscitation in comparison with the LCT/MCT emulsion. 11 We hypothesized that LCT emulsions presented a superior pharmacokinetic profile compared with LCT/MCT emulsions in the SD rats infused with bupivacaine. Accordingly, we established a rat model to compare the effectiveness of LCT versus LCT/MCT emulsions in such treatment.
METHODS

Animal Preparation
All studies were conducted with the approval of the Wenzhou Medical University Animal Care and Use BACKGROUND: Lipid infusions have been proposed to treat local anesthetic-induced cardiac toxicity. This study compared the effects of long-chain triglyceride (LCT) emulsions with those of long-and medium-chain triglyceride (LCT/MCT) emulsions on the pharmacokinetics of bupivacaine in a rat model. METHODS: After administration of intravenous infusion of bupivacaine at 2 mg·kg −1 ·min −1 for 5 minutes in Sprague-Dawley (SD) rats, either Intralipid 20%, an LCT emulsion (LCT group, n = 6), or Lipovenoes 20%, an LCT/MCT emulsion (LCT/MCT group, n = 6), was infused at 2mg·kg −1 ·min −1 for 5 minutes. The concentrations of total plasma bupivacaine and bupivacaine that were not bound by lipid (lipid unbound) were measured by a liquid chromatography-tandem mass spectrometric method. A 2-compartmental analysis was performed to calculate the lipidbound percentage of bupivacaine and its pharmacokinetics. RESULTS: In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min −1 ·kg −1 , P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg −1 , P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min −1 , P = .021, P′ = .032) were larger; and the area under the blood concentration-time curve 0 − t; (605 ± 82 vs 867 ± 110 mgL −1 ·min −1 , P = .001) and the area under the blood concentration-time curve (0 − ∞) (697 ± 111 vs 991 ± 121 mgL −1 ·min −1 , P = .001) were less, when compared with the LCT/MCT group. CONCLUSIONS: LCT emulsions are more effective than LCT/MCT emulsions in the metabolism of bupivacaine through demonstration of a superior pharmacokinetic profile. (Anesth Analg 2016;123:1116-22) Committee (Wenzhou, China). Healthy male specific pathogen-free Sprague-Dawley rats, 7 to 8 weeks old, were purchased and housed in plastic cages (4 rats per cage) at the animal center of Wenzhou Medical University in a standard 12-hour reverse day/night cycle at an ambient temperature of 19°C to 25°C and a humidity of 55% to 60%. The rats had an ad libitum diet of stock laboratory nutrition (Beijing Keao-Xieli Feedstuff Co., Ltd., Beijing, China) and tap water. After the animals exhibited adequate weight gain, 12 rats aged 8 to 10 weeks, weighing 300 to 400 g, were entered into subsequent studies.
The rats were fasted for 12 hours before the experiments, but they had free access to water. On the day of the experiment, the rats were anesthetized with an intraperitoneal injection of urethane (1600 mg/kg). Tracheal intubation was performed via tracheotomy, and the rats were mechanically ventilated with 1% to 2% sevoflurane in 100% oxygen, using a rodent volume-controlled ventilator (tidal volume = 8 mL·kg −1 , rate = 75-80 breaths·min −1 , inspiratory/ expiratory ratio = 2:3, HX-100E, TME Technology Co., Ltd., Chengdu, China). The right femoral artery was cannulated for arterial blood pressure monitoring and sample collection. The right femoral vein was cannulated for administration of medications. Body temperature was maintained at 38°C to 39°C using a thermal insulation blanket underneath the body and a heating lamp that was kept at a safe distance. Hemodynamics and electrocardiographic data were recorded by a data archiving and retrieval system (RM6240, TME Technology Co., Ltd.). On completion of the invasive procedures, all animals were allowed to stabilize physiologically for 15 minutes (to recover from induction of anesthesia and invasive monitor/device insertion). After stabilization, 0.2 mL of arterial blood was drawn for blood gas analysis.
Pharmacokinetics
The 12 male SD rats were divided into an LCT group (n = 6) and an LCT/MCT group (n = 6) according to a random number table. At the end of the stabilization period (baseline time, designated T base ), bupivacaine hydrochloride (Sigma-Aldrich Co., St. Louis, MO) was infused at 2 mg·kg −1 ·min −1 for 5 minutes via the right femoral vein. Once the infusion of bupivacaine was completed (designated as 0 minutes), all rats were infused with either 20% Intralipid (Huarui Pharmaceuticals Co. Ltd., Wuxi, China) or 20% Lipovenoes (Huarui Pharmaceuticals Co.Ltd., Wuxi, China) at 2 mL·kg −1 ·min −1 for 5 minutes. Blood samples of 1 mL were collected at 0, 2, 5, 10, 20, 30, 45, 60, 90, 120, 240, and 360 minutes. After the last blood draw, the rats were euthanized by the use of a lethal injection of air through the femoral vein.
After each sample was collected, the rats were administered an equal volume of blood that had been taken from the other healthy male SD rats. Blood was centrifuged (4000 rpm, 10 minutes) to obtain a plasma supernatant; 200 µL plasma was collected for measurement of the total plasma bupivacaine. The remaining plasma was recentrifuged (10 000 rpm, 10 minutes). The aqueous phase (substratum) was extracted by a pipette through the lipid-rich supernatant for measurement of the plasma concentration of bupivacaine that was lipid unbound. All the samples were stored at −80°C for further analysis.
Measurement of Bupivacaine
On the basis of our previous report, 14 plasma concentrations of total bupivacaine and bupivacaine lipid unbound were determined by the liquid chromatography-tandem mass spectrometric method (Bruker Esquire; Bruker Company, Karlsruhe, Germany).
A standard bupivacaine curve was prepared by adding a known concentration of bupivacaine to the plasma obtained from rats that were not infused with bupivacaine (0.04-20 μg·mL −1 , n = 5, repeated for 5 days). A plasma volume of 50 μL was added to 50 ng of ropivacaine as an internal standard, and 0.05 mmol KOH for alkalization, 1 mL N-hexane, and 4 mL acetoacetate were used for extraction of bupivacaine. The preparations were mixed with a vortex generator for 1 minute and centrifuged at 2500 rpm for 10 minutes. The upper organic phase was neutralized and acidified with 0.3 mL of 1.5% HCl solution, and it was then mixed with a vortex generator for 1 minute, followed by centrifugation at 2500 rpm for 10 minutes. An aqueousphase subnatant of 0.25 mL was taken for the determination of bupivacaine levels.
The correlation coefficient value of (r) 2 was >0.999. The lower limit of detection for bupivacaine was 5 ng·mL −1 . Within-day and day-to-day coefficients of variation of bupivacaine were <6%. Recovery of bupivacaine from plasma ranged from 92.5% to 109.3%.
Pharmacokinetic Analysis
Pharmacokinetic parameters of bupivacaine in plasma were calculated by a 2-compartmental analysis based on the data obtained from the end of bupivacaine infusion until the time of the last sample using DAS version 2.0 (Drug and Statistics, Mathematical Pharmacology Professional Committee of China, Shanghai, China).
The volume of distribution (Vd; Vd = Dose/C, where C = total plasma bupivacaine concentration) was defined as the volume of plasma that would be necessary to account for the total amount of bupivacaine in the subject's body, with the assumption that bupivacaine was present throughout the body at the same concentration as found in the plasma. Elimination half-life was designated as t 1/2 and was calculated as t 1/2 = 0.693/λz. The area under the blood concentration-time curve (AUC) was determined using the trapezoidal method. Clearance (CL) was defined as the Vd removed from the body per unit time and was calculated as CL = Dose/AUC. K10 represents a rate constant of drug elimination from the central compartment, K12 as that from the central compartment to the peripheral compartment, and K21 as that from the peripheral compartment to the central compartment.
Dynamic Lipid-Bound Percentage of Bupivacaine
The dynamic lipid-bound percentage of bupivacaine was defined as the percentage of lipid-bound bupivacaine concentration compared with the total bupivacaine concentration in plasma (at each time point through blood sampling), and it was calculated by using the following equations: 
Statistical Analysis
The determination of the number of animals in the LCT group and the LCT/MCT group was based on our preliminary study (n = 4), in which the Vd of bupivacaine was 0.54 ± 0.10 L·kg −1 and 0.32 ± 0.08 L·kg −1 , respectively. A sample size of 5 per group was obtained by Power Analysis and Sample Size [PASS] 11.0, with α = .05 and β = .1. We enrolled 6 rats per group to account for attrition.
Statistical analysis was performed using SPSS 15.0 (SPSS Inc, Chicago, IL) for Windows (Microsoft, Redmond, WA). The residuals of the 2-group model were checked for normality using a Shapiro-Wilk test. The data of blood gas and pharmacokinetics were presented as mean ± SD. Differences in arterial blood gas and pharmacokinetic parameters of total bupivacaine plasma concentrations were analyzed with the independent-sample t test. Values of P < .05 were considered significant. When the P value was between .01 and .15, Wilcoxon rank-sum test was applied as sensitivity analysis, which was defined as P' value. The data of mean blood pressure and heart rate were presented as mean and 95% confidence intervals. Differences in mean arterial blood pressure, heart rate, and dynamic percentage of lipid-bound bupivacaine at each time point in 2 groups were examined by 2-way repeated-measure analysis of variance. Curve fitting and bar charts were performed by GraphPad Prism v5.0 (GraphPad Software Inc, San Diego, CA).
RESULTS
Baseline Values and Hemodynamics
Mean values of the baseline of blood gas were similar in both groups (Table 1) , as were the mean arterial blood pressures and heart rates (Figure 1 ).
Pharmacokinetic Parameters
The comparison of pharmacokinetic parameters between the 2 groups is shown in Table 2 . The LCT group had an increased plasma bupivacaine elimination CL (15 ± 2 vs 10 ± All data are presented as mean ± SD. For each group, n = 6. There is no statistically significant difference of blood gas between 2 groups. Abbreviations: LCT, long-chain triglyceride; LCT/MCT, long-and medium-chain triglyceride. Figure 1 . Mean and 95% confidence intervals of heart rate and mean arterial blood pressure of long-chain triglyceride (LCT) groups and long-and medium-chain triglyceride (LCT/MCT) groups are shown during T base to 360 minutes, n = 6. There is no statistically significant difference with regard to blood pressure and heart rate between the 2 groups (F = 0.096, df = 1, P = .763 for mean blood pressure, F = 0.116, df = 1, P = .74 for heart rate). 1 mL·min −1 ·kg −1 , P = .003), Vd (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg −1 , P = .007), and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min −1 , P = .021, P′ = .032), while exhibiting reduced AUC (0 − t) (605 ± 82 vs 867 ± 110 mg L −1 ·min −1 , P = .001) and AUC (0 − ∞) (697 ± 111 vs 991 ± 121 mg L −1 ·min −1 , P = .001) as compared with the LCT/MCT group. The comparison of the t 1/2 α , t 1/2 β, K10, and K12 between groups demonstrated no statistical significance.
Plasma Bupivacaine Concentration
The concentration-time curve of total or bound bupivacaine between the 2 groups is presented in Figure 2 . In the LCT/MCT group, the LCT/MCT lipid unbound was higher at 5 minutes than that at 2 minutes in all rats (34 ± 9 vs 23 ± 7 mg/L). Total, lipid-bound, and lipid-unbound bupivacaine concentrations are shown in Figure 3 .
Lipid-bound Percentage
The lipid-bound percentage of bupivacaine is shown in Table 3 . Based on the unequal variances and 99% confidence interval (−6.9 to 23.5) of the present sample size, it could not be detected whether there was a difference in the dynamic percentage of lipid-bound bupivacaine between LCT and LCT/MCT groups.
DISCUSSION
Our pharmacokinetic analysis using a 2-compartmental analysis model demonstrated that the LCT group had an increased Vd of bupivacaine, increased CL, and K21 elimination rates, and these were accompanied by reduced AUC (0 − t) and AUC (0 − ∞) as compared with the LCT/MCT group. As in our previous study, 14 we used a model of bupivacaine toxicity without cardiac arrest. A cardiac arrest model would prolong recovery time and lead to inconsistent hemodynamics, thereby complicating the determination of bupivacaine pharmacokinetics, particularly when a lipid infusion is used for resuscitation. In addition, accumulation of lactate would occur in the cardiac arrest model, thus inducing a higher degree of dissociation of bupivacaine and a decrease in the binding capacity of lipid emulsion or plasma protein. As a result, the free concentration of bupivacaine in plasma might increase. Because the factors cited earlier would influence the results of this experiment, we chose to use a model without cardiac arrest.
LCT and LCT/MCT emulsions have different binding capacities. 6, 7 Because of these differences, infusions of lipid emulsions (in vivo) can change the Vd of bupivacaine. Vd is inversely proportional to plasma concentration when the quantities of bupivacaine remain unchanged. Our results demonstrated that LCT emulsions reduced plasma bupivacaine concentration more effectively than did LCT/MCT emulsions, as demonstrated by a higher Vd and a reduced AUC (0 − t) and AUC (0 − ∞).
LCTs, the main components of lipid emulsion, have an affinity for the liver. 15 Bupivacaine is a lipid-soluble drug, binding tightly to a lipid emulsion. The higher bupivacaine elimination CL in the LCT group suggested that the liver might be more facile in its uptake of bupivacaine because of the presence of these LCTs. If LCT emulsions could more effectively deliver bupivacaine to the liver and contribute to a higher elimination of CL, this might be a significant contribution to the accelerated transport from the peripheral compartment to the central compartment, thereby explaining the higher K21 in the LCT group.
Lipids were traditionally believed to be partially hydrolyzed into glycerine and fatty acids by lipoprotein lipase located in the vascular endothelium, 16 with further hydrolysis by hepatic lipase after liver uptake. 17 Both the binding and the hydrolysis of lipids were dynamic processes that could take place simultaneously. In our investigation, the lipid-binding effect observed in the vivo rat model was a dynamic characteristic. However, there was no statistically significant difference between LCT and LCT/MCT groups. It is not appropriate to make a conclusion, because we could not detect an important difference based on the confidence interval of the present sample size. Clinically, it is an acute and transient process (<30 minutes) that deals with the cardiac toxicity of local anesthetics and toxicity rescue by lipid emulsion. Also, the plasma concentrations of local anesthetics and lipid emulsions change rapidly during this process. In this study, we researched the effect of lipid emulsion on the pharmacokinetics of bupivacaine. Pharmacokinetic parameters were the primary content of this research. The observation time of protocol was defined as 360 minutes. The extended observation time may explain why there was no statistical difference between 2 groups in the comparison of the dynamic percentage of lipid-bound bupivacaine. Because the half-lives of LCT and LCT/MCT emulsions were 33 and 17 minutes, 18 respectively, the LCT/MCT emulsion was degraded more quickly than the LCT emulsion. [18] [19] [20] [21] [22] The hydrolysis rate of triglycerides in the LCT/ MCT emulsions was 3 to 5 times more than that of the LCT emulsions. 23 It was responsible for a higher quantity of lipid-bound bupivacaine that was released into the plasma by hydrolysis. Thus, lipid-unbound bupivacaine in the LCT/MCT group subsequently increased. The dynamic lipid-bound percentage of bupivacaine and the self-hydrolysis rate of a lipid emulsion might be the explanation as to why the Vd of bupivacaine, secondary to an LCT emulsion, is higher. In the initial 2 minutes of lipid emulsion transfusion, the redistribution of bupivacaine is reflected by the dramatic decrease of total plasma bupivacaine concentrations (63% in the LCT group, 48% in the LCT/MCT group). The total plasma concentration of bupivacaine and its lipid-unbound portion were higher at 5 minutes than at 2 minutes in the LCT/MCT group. Compared with the LCT group, the free concentration of bupivacaine in plasma is higher in the LCT/MCT group, because the LCT/MCT emulsion binds more local anesthetic than the LCT emulsion. 10 As a result, more bupivacaine enters into the circulation. Meanwhile, the LCT/MCT emulsion had a shorter elimination half-time (17 vs 33 minutes),which allowed a higher free concentration of bupivacaine in plasma. 18 The LCT emulsion also facilitated delivery of bupivacaine to the liver, which results in a decrease of bupivacaine in plasma. 12, 14 The reversal of bupivacaine toxicity by a lipid emulsion not only depends on bupivacaine binding but also leads to the improvement of cardiac function by providing myocardial energy. 12, 24 Furthermore, the LCT emulsion was associated with fewer recurrences of asystole after resuscitation and lower myocardial bupivacaine concentrations, as compared with the LCT/MCTemulsion. 11 It was important to note that, as compared with our previous study, 9 this study resulted in different pharmacokinetic parameters. This occurred primarily because of an adjustment, or modification, to a design deficiency in our previous study. In our current study, when a blood sample was drawn from the animal for testing, an equal amount of plasma was infused back to the animal, whereas, in the previous study, an equal amount of normal saline (as opposed to plasma) was administered as replacement. More specifically, a rat weighing 300 g loses 1 mL blood in each blood draw at 12 points in time, which would lead to a loss of 22.15% of total plasma protein during the experiment. Secondary to this plasma protein loss, the binding capacity of bupivacaine in plasma was also decreased, resulting in more bupivacaine moving toward tissue, and an increased bupivacaine elimination half-life. This may be the explanation as to why the half-life time of the LCT group in our previous study was lower than that in the present study (165 ± 35 vs 110 ± 25 minutes).
Our investigation has several limitations. First, we were unable to analyze/quantify the concentration of bupivacaine that was lipid unbound by using the compartmental analysis model because of the discrete values we employed. Second, the experimental error of bupivacaine concentration may occur in a repeated collection of blood samples and transfusion.
In our rat model of bupivacaine-induced cardiac depression, the LCT emulsion demonstrated an increased Vd, elimination of CL, along with a decreased AUC (0 − t) and AUC (0 − ∞) when compared with the LCT/MCT emulsion. LCT emulsions were more effective than LCT/MCT emulsions in the metabolism of bupivacaine through demonstration of a superior pharmacokinetic profile. The demonstrated superiorities of LCT emulsions in this study suggest that they may be more suitable in the treatment of local anesthetic-induced system toxicity. E
